SU9516

• Description :

  SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Autophagy; CDK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SU9516.html

• Purity :

  99.85

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C1NC2=C(C=C(OC)C=C2)/C1=C/C3=CN=CN3

• Molecular Formula :

  C13H11N3O2

• Molecular Weight :

  241.25

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug 15;61 (16) :6170-7.|[2]Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64 (7) :1091-100.|[3]Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1- (3H-imidazol-4-yl) -meth- (Z) -ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 2006 Aug;70 (2) :645-55.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK1; CDK2; CDK4

• CAS Number :

  [377090-84-1]